Savara (SVRA) Competitors $3.04 +0.04 (+1.16%) As of 09:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SVRA vs. APGE, TARS, ARQT, SPRY, IMCR, ADPT, SRPT, EWTX, BHVN, and MENSShould you be buying Savara stock or one of its competitors? The main competitors of Savara include Apogee Therapeutics (APGE), Tarsus Pharmaceuticals (TARS), Arcutis Biotherapeutics (ARQT), ARS Pharmaceuticals (SPRY), Immunocore (IMCR), Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), Edgewise Therapeutics (EWTX), Biohaven (BHVN), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry. Savara vs. Its Competitors Apogee Therapeutics Tarsus Pharmaceuticals Arcutis Biotherapeutics ARS Pharmaceuticals Immunocore Adaptive Biotechnologies Sarepta Therapeutics Edgewise Therapeutics Biohaven Jyong Biotech Apogee Therapeutics (NASDAQ:APGE) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk. Which has more volatility and risk, APGE or SVRA? Apogee Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Is APGE or SVRA more profitable? Apogee Therapeutics' return on equity of -34.65% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -34.65% -32.76% Savara N/A -63.82%-51.64% Do insiders and institutionals believe in APGE or SVRA? 79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 42.8% of Apogee Therapeutics shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, APGE or SVRA? Apogee Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$182.15M-$4.13-9.29SavaraN/AN/A-$95.88M-$0.48-6.34 Does the media favor APGE or SVRA? In the previous week, Apogee Therapeutics had 5 more articles in the media than Savara. MarketBeat recorded 14 mentions for Apogee Therapeutics and 9 mentions for Savara. Savara's average media sentiment score of 0.01 beat Apogee Therapeutics' score of -0.03 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Savara 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate APGE or SVRA? Apogee Therapeutics currently has a consensus target price of $99.00, indicating a potential upside of 157.98%. Savara has a consensus target price of $5.60, indicating a potential upside of 83.91%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Apogee Therapeutics is more favorable than Savara.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Savara 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryApogee Therapeutics beats Savara on 8 of the 13 factors compared between the two stocks. Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVRA vs. The Competition Export to ExcelMetricSavaraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$526.82M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-6.1022.0530.2925.74Price / SalesN/A742.42470.66115.79Price / CashN/A184.4138.2159.48Price / Book3.054.838.846.15Net Income-$95.88M$31.61M$3.25B$265.06M7 Day Performance15.34%4.55%3.72%2.60%1 Month Performance32.97%5.69%5.86%2.83%1 Year Performance-32.48%12.71%30.23%25.58% Savara Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVRASavara1.9904 of 5 stars$3.05+1.2%$6.20+103.6%-29.3%$526.82MN/A-6.1020News CoverageEarnings ReportAPGEApogee Therapeutics3.0491 of 5 stars$37.24-1.4%$99.00+165.8%-13.8%$1.74BN/A-10.3491News CoverageEarnings ReportAnalyst RevisionTARSTarsus Pharmaceuticals1.7931 of 5 stars$41.91+2.7%$66.67+59.1%+103.1%$1.71B$182.95M-15.3550News CoverageInsider TradeARQTArcutis Biotherapeutics1.6477 of 5 stars$14.52+1.6%$19.40+33.6%+66.8%$1.70B$196.54M-13.96150Gap DownSPRYARS Pharmaceuticals2.4715 of 5 stars$17.38+1.2%$31.00+78.4%+11.3%$1.69B$89.15M-108.6290News CoverageEarnings ReportIMCRImmunocore1.944 of 5 stars$32.53-1.4%$58.89+81.0%-10.6%$1.66B$310.20M-75.65320News CoverageAnalyst RevisionADPTAdaptive Biotechnologies2.8292 of 5 stars$10.91+5.6%$11.33+3.9%+193.6%$1.57B$178.96M-11.36790SRPTSarepta Therapeutics4.6199 of 5 stars$17.10+7.5%$49.12+187.3%-84.7%$1.56B$1.90B-6.361,372Trending NewsShort Interest ↑EWTXEdgewise Therapeutics2.2881 of 5 stars$13.61-4.9%$40.55+197.9%-18.3%$1.51BN/A-8.7860News CoverageInsider TradeGap UpBHVNBiohaven3.5782 of 5 stars$14.70-0.1%$58.46+297.8%-62.7%$1.50BN/A-1.57239Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMENSJyong BiotechN/A$23.46+22.7%N/AN/A$1.45BN/A0.0031News CoverageGap Down Related Companies and Tools Related Companies APGE Alternatives TARS Alternatives ARQT Alternatives SPRY Alternatives IMCR Alternatives ADPT Alternatives SRPT Alternatives EWTX Alternatives BHVN Alternatives MENS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVRA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access